Loyal is a clinical-stage biotechnology company based in San Francisco, California, founded in 2020. The company is dedicated to developing prescription drugs aimed at extending the healthy lifespan and improving the quality of life for dogs. Loyal focuses on preventive care by addressing age-associated diseases and metabolic dysfunction in dogs, particularly large breeds. The company is led by CEO Celine Halioua and has raised over $116.81 million in funding, with ongoing efforts to secure FDA approvals through its Center for Veterinary Medicine. Loyal's drug development pipeline includes three main products targeting longevity and healthy aging in dogs. LOY-002 is designed for senior dogs and aims to correct metabolic dysfunction, while LOY-001 and LOY-003 focus on correcting IGF-1 and growth hormone overexpression in large dogs. The company is conducting a nationwide clinical study called STAY, enrolling 1,300 senior dogs across 70 veterinary clinics. Loyal emphasizes partnerships with veterinary professionals for the administration of its products and conducts research involving DNA sequencing from canine saliva samples.
Enter your details and select criteria for the jobs you want to receive.
Loyal is seeking a Senior Director of Clinical Development to lead veterinary drug clinical programs for a clinical-stage company developing longevity medicines for dogs on the path toward FDA approval.
